At a major medical meeting in June, Bristol will unveiled the detail report about how much longer the melanoma patients will survive after take a Bristol drug, ipilimumab. In November, The Food and Drug Administration (FDA), delayed ipilimumab approval to give it more time to review data on the medicine, setting a new action date [...]

An experimental drug being developed by Bristol-Myers Squibb Co. when used with chemotherapy appeared to keep advanced lung cancer from progressing modestly longer than chemotherapy alone, according to a summary of data from a mid-stage study. The biotechnology drug ipilimumab, which augments the body’s immune response by inhibiting certain proteins, kept advanced non-small cell lung [...]